A major review published in JAMA has laid out the clearest picture yet of alcohol-related liver disease, a condition that has quietly become the leading cause of liver-related illness and death worldwide, and the most common reason for liver transplants across Europe and the United States. Written by Aleksander Krag, Fredrik Åberg, and Jessica Mellinger, alongside a team of hepatology specialists, the review draws together decades of evidence on how the disease develops, why it so often goes undetected, and what actually works to stop it.

The Scale of the Problem

The review’s headline figure is stark. In the US, deaths linked to alcohol-related liver disease nearly doubled between 1999 and 2022, rising from 6.7 to 12.5 per 100,000 people. That trend lines up closely with a separate national mortality analysis, which found that the rate of increase accelerated sharply after 2018, nearly tripling compared with the pace seen in the years before.

How Little Alcohol It Actually Takes

One of the review’s more striking findings is just how modest the threshold for harm can be. Long-term daily drinking above roughly 20 grams of pure alcohol for women, and 30 grams for men, is enough to set alcohol-related liver disease in motion. A single standard drink contains about 14 grams of ethanol, roughly a 12-ounce beer, a 5-ounce glass of wine, or a 1.5-ounce measure of spirits. That means fewer than one and a half drinks a day for women, and just over two for men, sustained over time, is enough to start the process.

The disease does not arrive all at once. It typically begins as reversible fatty build-up in the liver, known as steatosis, before potentially advancing to inflammation, scarring, and eventually cirrhosis. From there, complications can include internal bleeding, fluid build-up in the abdomen, confusion caused by toxins reaching the brain, and liver cancer.

Who Is Most at Risk

The review identifies a clear set of factors that push the disease toward faster progression: greater quantity and duration of alcohol use, female sex, older age, obesity, type 2 diabetes, metabolic syndrome, smoking, viral hepatitis, and certain genetic variants. Female sex stands out in particular. A separate national mortality study found that although men still die from alcohol-related liver disease at higher absolute rates, women’s death rates have been rising nearly twice as fast as men’s over the past two decades, with cirrhosis deaths among women climbing more than eight per cent a year since 2011.

Why It So Often Goes Unnoticed

Perhaps the most important detail in the review is that around 90 per cent of people with alcohol-related liver disease have no symptoms at all, or only vague ones such as tiredness that are easy to dismiss. It is often only once the disease has progressed to alcohol-associated hepatitis or decompensated cirrhosis that clearer signs emerge: fever, nausea, abdominal pain, jaundice, swelling, or bleeding.

Catching the Disease Before It Catches Up

The review highlights a growing toolkit of non-invasive tests that can flag trouble early. The Fibrosis-4 score, calculated from routine blood markers, liver enzymes, platelet count, and age, offers a simple first step. More detailed follow-up tests, including liver stiffness measurement and blood-based fibrosis markers, can then assess how much scarring has occurred, which the authors describe as the strongest predictor of long-term liver outcomes.

Because people often underreport how much they drink, the review points to screening tools such as the Alcohol Use Disorders Identification Test, alongside biological markers like blood phosphatidylethanol, as ways of building a more accurate picture of someone’s actual intake.

Stopping Drinking Remains the Most Powerful Treatment

If there is one message running through the review, it is this: sustained abstinence from alcohol is by far the most effective way to halt and even reverse the course of the disease. Among people already living with alcohol-related cirrhosis, those who stopped drinking saw their risk of dying from liver disease fall by more than half, and their overall risk of death drop by 55 per cent, over roughly three years of follow-up.

Support for reaching abstinence includes structured approaches such as motivational enhancement therapy and cognitive behavioural therapy, alongside medications like baclofen and naltrexone where appropriate. For those whose disease has progressed to severe alcohol-associated hepatitis or decompensated cirrhosis, liver transplant evaluation becomes an important consideration.

The Bigger Picture

Taken together, the review and the wider research around it point to a disease that develops in ordinary people, drinking at levels many would consider unremarkable, over years of quiet, cumulative damage, and one whose burden is now shifting toward groups not traditionally seen as high risk, particularly women. Early testing, honest conversations about drinking habits, and a genuine commitment to cutting alcohol out altogether remain the clearest path to protecting long-term liver health.

Source: JAMA Network